| Literature DB >> 20176575 |
H A Jinnah1, Irene Ceballos-Picot, Rosa J Torres, Jasper E Visser, David J Schretlen, Alfonso Verdu, Laura E Laróvere, Chung-Jen Chen, Antonello Cossu, Chien-Hui Wu, Radhika Sampat, Shun-Jen Chang, Raquel Dodelson de Kremer, William Nyhan, James C Harris, Stephen G Reich, Juan G Puig.
Abstract
Lesch-Nyhan disease is a neurogenetic disorder caused by deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase. The classic form of the disease is described by a characteristic syndrome that includes overproduction of uric acid, severe generalized dystonia, cognitive disability and self-injurious behaviour. In addition to the classic disease, variant forms of the disease occur wherein some clinical features are absent or unusually mild. The current studies provide the results of a prospective and multi-centre international study focusing on neurological manifestations of the largest cohort of Lesch-Nyhan disease variants evaluated to date, with 46 patients from 3 to 65 years of age coming from 34 families. All had evidence for overproduction of uric acid. Motor abnormalities were evident in 42 (91%), ranging from subtle clumsiness to severely disabling generalized dystonia. Cognitive function was affected in 31 (67%) but it was never severe. Though none exhibited self-injurious behaviours, many exhibited behaviours that were maladaptive. Only three patients had no evidence of neurological dysfunction. Our results were compared with a comprehensive review of 78 prior reports describing a total of 127 Lesch-Nyhan disease variants. Together these results define the spectrum of clinical features associated with hypoxanthine-guanine phosphoribosyltransferase deficiency. At one end of the spectrum are patients with classic Lesch-Nyhan disease and the full clinical phenotype. At the other end of the spectrum are patients with overproduction of uric acid but no apparent neurological or behavioural deficits. Inbetween are patients with varying degrees of motor, cognitive, or behavioural abnormalities. Recognition of this spectrum is valuable for understanding the pathogenesis and diagnosis of all forms of hypoxanthine-guanine phosphoribosyltransferase deficiency.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20176575 PMCID: PMC2842514 DOI: 10.1093/brain/awq013
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Case demographics
| 1–1 | None | 239-240delGA insTT | D80F | ND (EL) | Motor delay and posturing | 0.5 | 3.4 | Multiple scars on hands | Allopurinol, diazepam | None |
| 2–2 | PB | IVS4-1G>A | Splice error | ND (EL) | Nephrolithiasis | 0.25 | 7 | Allopurinol | None | |
| 3–3 | JLY | IVS1+1G>A | Splice error | 0.1% (EL) | Hypotonia | 0.5 | 7 | Nephrolithiasis, hydronephrosis | Allopurinol, baclofen | (Marcus |
| 4–4 | Zarazoga I | G397A | V133M | 9.4% (EL), 54% (LE) | Renal failure | Infancy | 8 | Renal insufficiency | Allopurinol | (Jinnah |
| 5–5 | NF | T203C | L68P | ND (EL) | Motor delay | 0.5 | 9 | Nephrocalcinosis | Allopurinol | None |
| 6–6 | DoA | G143A | R48H | ND (EL) | Motor delay | 2 | 9 | Nephrolithiasis | Allopurinol | None |
| 7–7 | JW | C193T | L65P | 10% (EL) | Motor delay | 6 | 10 | Hypertension | Allopurinol, cetirizine | (Srivastava |
| 8–8 | P4 | None | mRNA decrease | 6% (EL), 98% (LE) | Hyperuricaemia | 10 | 10 | NA | (Garcia | |
| 9–5 | DiA | T203C presumed | L68P | 7% (EL) | Motor delay | 2 | 11 | NA | Allopurinol | None |
| 10–8 | P3 | None | mRNA decrease | 6% (EL), 98% (LE) | Hyperuricaemia | 12 | 12 | NA | (Garcia | |
| 11–9 | JF | T548C | I183T | <1% (EL) 8% (LF) | Motor delay | Infancy | 14 | NA | Allopurinol | (Hersh |
| 12–8 | P2 | None | mRNA decrease | 6% (EL), 98% (LE) | Hyperuricaemia | 15 | 16 | NA | NA | (Garcia |
| 13–10 | IRdL | IVS4-2A>G | Splice error | ND (EL), 0.1% (LE) | Motor delay | 16 | 16 | NA | Allopurinol | (Torres |
| 14–11 | RB | G601A | D201N | 60% (LF) | Crystalluria | 0.5 | 17 | Nephrolithiasis | Allopurinol, metoprolol, amlodipine | (Sege-Peterson |
| 15–9 | BF | T548C | I183T | <1% (EL) 8% (LF) | Crystalluria | 1 | 17 | NA | Allopurinol | (Hersh |
| 16–12 | Madrid I | G212T | G71V | ND (EL), 0.2% (LE) | Motor delay | 1 | 17 | Nephrolithiasis, hypertension, macrocytic anaemia | Allopurinol, baclofen, nifedipine | (Bouwens-Rombouts |
| 17–13 | BT | G599C | R200T | 0-26% (EL) | Hypotonia | 2 | 17 | Nephrolithiasis, macrocytic anaemia | Allopurinol | (Hidalgo-Laos |
| 18–14 | TH | G143A | R48H | ND (EL), 39% (LF) | ADHD | 6 | 17 | Macrocytosis | Allopurinol | None |
| 19–15 | None | G500C | R167T | 8.7% (LL) | Nephrolithiasis, gout | 10 | 17 | Nephrolithiasis, cystitis, gout | Allopurinol | None |
| 20–16 | VC | G143A | R48H | ND (EL) | Motor delay | <1 | 18 | NA | Allopurinol | (Larovere |
| 21–17 | None | A584C | Y195S | ND (EL) | Uric acid crystal in finger | 14 | 18 | NA | NA | (Larovere |
| 22–18 | MM | IVS1+1 G>T | Splice error | 5% (EL), 1% (LF) | Motor delay | 1 | 20 | Multiple scars on chin | Allopurinol, trihexyphenidyl, balcofen, diazepam | (Jinnah |
| 23–14 | GH | G143A | R48H | 15% (LF) | Clumsiness | 2.5 | 20 | Macrocytosis | Allopurinol | None |
| 24–19 | P1 | None | Decreased mRNA | 5% (EL), 64% (LE) | Hyperuricaemia | 14 | 20 | Hypothyroidism | Allopurinol | (Garcia |
| 25–20 | Santona (family S2) | T125C | I42T | ND (EL), 0.6% (LE) | Motor delay, dystonic postures | 14 | 21 | NA | Allopurinol | (Puig |
| 26–21 | None | A602G | Splice error | NA | Gout | 2 | 23 | Gout, migraines, macrocytic anaemia | Allopurinol, baclofen | None |
| 27–22 | None | A584C | Y195S | ND (EL) | Motor delay | 2 | 24 | Tophi, renal insufficiency, nephrolithiasis, dysphornism | Allopurinol, enalapril | (Larovere |
| 28–23 | Madrid II (family G) | G143A | R48H | 0.3% (EL), 9.2% (LE) | Dystonic gait | 13 | 24 | Allopurinol | (Andres | |
| 29–5 | HA | T203C | L68P | AFM | Motor delay | 2.3 | 27 | Nephrolithiasis | Allopurinol | None |
| 30–24 | DD | G143A | R48H | 20% (LF) | NA | 29 | 29 | NA | Allopurinol | (Sege-Peterson |
| 31–25 | Tsou | G152A | R51Q | NA | Gout | 13 | 30 | Tophi | Allopurinol | (Chang |
| 32–26 | DM; GM 1622 | E2-3 duplication | Partial reversion | ND (EL), 1.6% (LF) | Motor delay | 0.5 | 31 | Multiple scars on all limbs | Allopurinol | (Gottlieb |
| 33–27 | Sardinia | C463T | P155S | ND (EL or LE), 2-4% (LF) | Motor delay | 1–2 | 32 | Gout, nephrolithiasis, G6PD deficiency | Allopurinol | (Cossu |
| 34–28 | LW | G148C | A50P | 2.5 (LF) | Motor delay | 0.6 | 34 | Nephrolithiasis | Allopurinol, diazepam | (Sege-Peterson |
| 35–22 | None | A584C | Y195S | ND (EL) | Gout | 19 | 35 | NA | (Larovere | |
| 36–16 | None | G143A presumed | R48H | AFM | Motor delay | 1.5 | 37 | Gout, recurrent tophi, nephrolithiasis | Allopurinol | (Larovere |
| 37–29 | Salamanca | T128G, G130A | M34R, D44N | 7.8% (LF) | Motor delay | 1.5 | 42 | NA | Allopurinol | (Page |
| 38–30 | LP | T596G | F199C | 8% (EL) | Motor delay | 2.3 | 43 | Nephrolithiasis, gout | Allopurinol | (Ea |
| 39–29 | Salamanca | T128G, G130A | M34R, D44N | 7.8% (LF) | Motor delay | 6 | 45 | NA | Allopurinol | (Page |
| 40–25 | Tsou | G152A | R51Q | NA | Gout | 30 | 45 | Tophi | Allopurinol | (Chang |
| 41–31 | Arlington | A239T | D80V | ND (EL) | Motor delay | 5 | 46 | Hypertension, migraines | Allopurinol | (Davidson |
| 42–32 | Chia-yi | T93G | D31E | 5% (EL) | Gout | 27 | 53 | Nephrocalcinosis | Allopurinol | (Wu |
| 43–16 | G143A | R48H | AFM | Tophus on knee | 28 | 56 | Tophi, nephrolithiasis, renal insufficiency, diabetes mellitus | Allopurinol, glibencamide | (Larovere | |
| 44–33 | Moosejaw | C582G | D194E | 10.8% (EL) | NA | 58 | NA | Allopurinol | (Jinnah | |
| 45–34 | Marseille | T407C | I136T | 1.4% (EL), 5.4% (L) | Gout | 40 | 60 | Severe gouty arthritis, urate nephropathy, scoliosis | Allopurinol | (Dussol |
| 46–33 | Moosejaw | C582G | D194E | 8.4% (EL) | Haematuria | 22 | 65 | Gout, tophi, macrocytic anaemia, renal insufficiency | Allopurinol | (Snyder |
Some information was not available (NA) because knowledgeable informants or records could not be located. For nosological classification, a BFM score of 6 or more was used to define patients as having HPRT-related neurological dysfunction (HND), while those with scores of 5 or below were considered to have HPRT-related hyperuricaemia (HRH).
aResults are shown as percent of normal control from different assays used in different clinical laboratories as noted: AFM = testing conducted in affected family member only; EL = erythrocyte lysates, FL = fibroblast lysates, LE = live erythrocytes, LF = live fibroblasts, LL = lymphocyte lysates. If normal controls were presented as a range, the percent of control was based on the lower limit of normal.
bThe test result varied according to phosphoribosyl pyrophosphate substrate applied.
cGenomic DNA revealed the base substitution A602G predicting D201G, but mRNA showed exclusion of exon 8, suggesting a coding region error leading to a splicing defect.
dDysmorphic features included coarse facial features and hair, very short thumbs and great toes, and clubbed first and second fingers.
Neurological features
| 1–1 | Moderate dystonic dysarthria | Limited by dystonic posturing but stands with support | Moderate generalized dystonia affecting face, trunk, limbs | 48 | Brisk leg reflexes, ankle clonus | NA | Aggressive | Hypotonia and posturing at 6 months; stable by 2 years |
| 2–2 | Severe dystonic dysarthria | Severe posturing prevents standing or walking | Severe generalized dystonia affecting face, neck, trunk, limbs | 66 | Brisk leg reflexes, ankle clonus | NA | Aggressive, coprolalia, ‘likes to flirt with danger’ | Motor and speech delay noted by 1 year; involuntary movements by 2 years; stable thereafter |
| 3–3 | Severe dystonic dysarthria | Severe posturing prevents standing or walking | Severe generalized dystonia affecting face, neck, trunk, limbs | 82.5 | Mild leg spasticity | Poor attention | Oppositional behaviour | NA |
| 4–4 | Normal | Normal | Mild overflow posturing of hands | 2 | Poor attention, IQ = 89 | Normal | Floppy head noted at 6 months; normal thereafter | |
| 5–5 | Severe dystonic dysarthria | Severe posturing prevents standing or walking | Severe generalized dystonia affecting face, neck, trunk, limbs; rare myoclonic jerks | 47 | Brisk arm and leg reflexes | Special education | Inappropriate affection, even with strangers | Motor and speech delay noted by 1 year; stable thereafter |
| 6–6 | Moderate dystonic dysarthria, hesitant, telegraphic | Normal but awkward running and hopping | Mild generalized dystonia | 19 | Brisk leg reflexes | Special education, IQ = 79 | Impulsive, oppositional | Motor and speech delay noted by 2 years; stable thereafter |
| 7–7 | Transient childhood speech disorder | Normal | Mild hand clumsiness with overflow posturing | 8 | ADHD, IQ = 108 | Onychophagia, impulsive, Asperger syndrome | Persistent stable clumsiness noted by 1 year; transient speech disorder | |
| 8–8 | Normal | Normal | Chronic tic disorder | 0 | Normal, IQ = 146 | Normal | None | |
| 9–5 | Moderate dystonic dysarthria | Independent but very slow and laboured with very stiff appearance | Moderate generalized dystonia with mild rigidity and myoclonic jerks | 34 | Brisk leg reflexes, ankle clonus | Special education | Normal | Motor and speech delay noted by 2–4 years; stable thereafter |
| 10–8 | Normal | Normal | Slightly slow/clumsy hand movements with exercise-induced dystonia | 7 | ADHD, IQ = 117 | Normal | None | |
| 11–9 | Normal | Independent but heavy appearance, awkward | Slow hand movements, overflow hand posturing | 2 | Brisk leg reflexes, ankle clonus, | IQ = 82 | Normal | Transient hypotonia in infancy |
| 12–8 | Slight dystonic dysarthria | Slightly slowed, reduced arm swing | Slow hand movements | 1 | None | Normal, IQ = 134 | obsessive-compulsive disorder | None |
| 13–10 | Moderate dystonic dysarthria | Leg spasms prevent standing or walking | Severe generalized dystonia | NA | Brisk leg reflexes, ankle clonus | Special education | Normal | Drinks 3l/day of water |
| 14–11 | Slightly indistinct | Independent but heavy appearance, cannot edge walk | Slow/clumsy limb movements, rare facial twitches | 3 | Ankle clonus | IQ = 56 | Normal | None |
| 15–9 | Tongue–jaw synkinesis and transient childhood speech disorder | Normal | Slow hand movements, tic-like shoulder shrug and head roll | 0.5 | Brisk leg reflexes, ankle clonus | IQ = 66 | Normal | Transient childhood speech impediment |
| 16–12 | Moderate dystonic dysarthria | Truncal hypotonia with dystonic leg posturing prevents standing or walking | Moderate generalized dystonia affecting face, neck, trunk, limbs; bradykinesia and rigidity without cogwheeling | 22.5 | Two seizures during childhood | IQ = 86 | Normal | Motor and speech delay noted by 1 year; involuntary movements 2–4 years; progressive gait disability from 8 years |
| 17–13 | History of stress-induced dysarthria | Normal | None | 0 | Brisk arm and leg reflexes, ankle clonus | Poor school performance, IQ = 86 | Severe onychophagia sometimes to bleeding | Motor delay and sialorrhea noted by 2 years; resolved thereafter |
| 18–14 | Normal | Normal | None | 0 | None | ADHD, IQ = 89 | Onychophagia, impulsive, bad behaviors (lying, stealing, etc.) | None |
| 19–15 | Mild dystonic dysarthria | Normal but cannot edge walk | Slightly slowed/clumsy hand movements | 7.5 | Brisk leg reflexes, ankle clonus | Normal | NA | NA |
| 20–16 | Slightly slow and indistinct | Slightly slowed | Hypomimia, slow hand movements with overflow posturing | 6 | Brisk leg reflexes, ankle clonus | Significantly impaired | Normal | Motor and speech delay noted by 2 years; stable thereafter |
| 21–17 | Hypophonic | Normal | Slightly slowed hand movements | 2 | None | Repeated 1st grade | Aggressive, labile mood, ‘rebellious’ | NA |
| 22–18 | Severe dystonic dysarthria | Severe posturing prevents standing or walking | Severe generalized dystonia affecting face, neck, trunk, limbs | 60 | Brisk arm and leg reflexes, reduced distal muscle bulk | IQ = 67 | None | Motor and speech delay noted by 1 year; progressive gait disability with falls from 6 to 12 years |
| 23–14 | Sightly slowed and indistinct, intermittent jaw dystonia, childhood stuttering | Normal except overflow hand posturing | Slow/clumsy hand movements | 7 | None | IQ = 83 | None | Clumsiness progressively apparent from 3 to 8 years; stable thereafter |
| 24–19 | Normal | Reduced arm swing | Slow arm and hand movements | NA | None | IQ = 97 | Normal | None |
| 25–20 | Severe dystonic dysarthria | Extreme leg spasms prevent standing or walking | Severe generalized dystonia | 12.5 | Brisk arm and leg reflexes, ankle clonus | ADHD, IQ = 86 | Anxiety disorder | None |
| 26–21 | Moderate dystonic dysarthria, childhood stuttering | Independent but very slow and laboured with very stiff appearance | Moderate generalized dystonia affecting face, neck, trunk, limbs; bradykinesia | 39 | None | ADHD, special education, IQ = 78 | Incarcerated for inappropriate behaviour | Motor and speech delay noted by 2 years; stable clumsiness until 9 years when stuttering speech began; progressive gait disability with falls at 18 years |
| 27–22 | Slightly indistinct | Normal but can’t edge-walking | Slow/clumsy hand movements | 6 | Brisk arm and leg reflexes, ankle clonus | Marked cognitive impairment | Aggressive | Motor and speech delay noted by 2 years; stable thereafter |
| 28–23 | Slight dystonic dysarthria | Mildly dystonic | Hypomimia, mild generalized dystonia, affecting face, trunk, limbs | NA | Brisk leg reflexes | Special education | Normal | None |
| 29–5 | Moderate dystonic dysarthria with jaw dystonia | Independent but hyperlordotic with very slow and laboured stiff appearance | Moderate generalized dystonia affecting face, trunk, limbs with bradykinesia, rigidity | 37 | Brisk leg reflexes, ankle clonus | Special education | Normal | Motor and speech delay noted at 2–4 years; stable thereafter |
| 30–24 | High-pitched nasal voice | Moderately slow with stiff appearance | Mild generalized dystonia affecting face and limbs | 16 | Brisk arm and leg reflexes, ankle clonus | IQ = 96 | Onychophagia when stressed | NA |
| 31–25 | Normal | Normal | Postural and kinetic tremor | NF | None | NA | Normal | None |
| 32–26 | Severe dystonic dysarthria | Severe posturing prevents standing or walking | Severe generalized dystonia affecting face, neck, trunk, limbs; occasional chorea and ballismic limb flailing | 61 | Reduced distal muscle bulk | IQ = 87, 77 | None | Motor and speech delay noted at 1 year; involuntary movements progressively apparent from 2 to 4 years; stable thereafter |
| 33–27 | Moderate dystonic dysarthria | Independent but very slow and stiff appearance with rare skip-like postural adjustments | Moderate generalized dystonia affecting face, trunk, limbs; bradykinesia | 16 | None | ADHD, IQ = 74 | Normal | Motor delay by 1 year, progressive clumsiness from 2–4 years, progressive gait disability beyond 20 years |
| 34–28 | Severe dystonic dysarthria | Truncal hypotonia with dystonic leg posturing prevents standing or walking | Resting hypotonia, severe generalized dystonia affecting face, neck, trunk, limbs; occasional choreiform and ballismic limb flailing | 68 | Brisk arm reflexes | IQ = 49 | Sits on arms to avoid hitting bystanders, story fabrication | Motor and speech delay with involuntary movements noted by 1 year; involuntary movements increasingly apparent through 30 years |
| 35–22 | Normal | Normal | Minor overflow posturing of one hand | 1 | None | Mild executive syndrome | Normal | None |
| 36–16 | Moderate dystonic dysarthria | Slightly slowed and heavy appearance | Slow/clumsy limb movements, stereotypical action-induced elevation of one shoulder | 11 | Brisk arm and leg reflexes, neuropathy | Poor school performance | Onychophagia | Motor and speech delay noted at 2–4 years; stable until >20 years when additional disability due to joint deformity began |
| 37–29 | Mild dystonic dysarthria with slight stuttering | Independent but hyperlordotic and stiff appearance | Slow/clumsy hand movements with overflow posturing | 14.5 | None | ADHD, could not finish public school, IQ = 68 | Onychophagia | Motor and speech delay noted at 2–4 years; stable clumsiness thereafter |
| 38–30 | Slightly slowed and indistinct | Slowed and stiff appearance; desires support at all times | Mild generalized dystonia with slow/clumsy hand movements | 22.5 | Brisk arm and leg reflexes | Frontal syndrome | Normal | Motor and speech delay by 2 years, sudden gait decline at 30 years after dropping daughter |
| 39–29 | Mild dystonic dysarthria with severe jaw dystonia and stuttering | Independent but hyperlordotic and stiff appearance | Blepharospasm | 5 | None | IQ = 68 | Normal | Motor and speech delay noted at 2–4 years; stable clumsiness thereafter |
| 40–25 | Normal | Impaired by joint deformities from tophaceous gout | None | 0 | None | Normal | Progressive disability due to joint deformity | |
| 41–31 | Slightly slowed and indistinct | Extreme leg spasms prevent standing or walking | Painful transient leg spasms, postural and kinetic tremor | 6 | None | Slow learner | Impulsive | Leg braces from 5 to 6 years, mild dystonic posturing until sudden decline at 40 years due to painful leg spasms |
| 42–32 | Normal | Normal | None | 0 | None | NA | Normal | None |
| 43–16 | Moderate dystonic dysarthria | Slightly slowed, cannot toe or heel walk due to joint deformity from tophaceous gout | NF | Brisk leg reflexes, peripheral neuropathy | NA | Emotional lability | Progressive hand disability due to joint deformity | |
| 44–33 | Slightly indistinct | Normal | Slight cogwheeling and slowing of hand movements | 5 | Brisk arm and leg reflexes, mild spasticity | Slow learner, IQ = 78 | Normal | None |
| 45–34 | Normal | Impaired by joint deformity from tophaceous gout | None | 4 | Normal, no testing | Normal | Progressive disability due to joint deformity beyond age 40 years | |
| 46–33 | Slightly indistinct with intermittent stuttering | Normal | Slight slowing of hand movements | 5 | Brisk arm and leg reflexes, mild spasticity | Slow learner, IQ = 93 | Normal | Stable stuttering since early childhood |
Some information was not available (NA). BFM = Burke–Fahn–Marsden dystonia rating scale; NF = not feasible because of severe tophaceous gout with joint deformity precluding meaningful motor exam or other confounding problems. The extensor plantar reflex was not included among the pyramidal signs because it could not be unequivocally distinguished from the dystonic toe response.
aBFM score taken at baseline, not after exercise.
bFunctional decline suspected to be psychogenic. One patient developed sudden deterioration of gait with examination features suggestive of fear of falling after he dropped his infant daughter. The other suddenly developed incapacitating painful leg spasms that were inducible following a minor knee injury. In both, there was no evidence for parallel deterioration of speech or hand skills.
Presenting features in previously reported cases
| Number ( | ||
|---|---|---|
| Neurological | 19 | 19.6 |
| Motor delay | 12 | 12.4 |
| Seizures | 3 | 3.1 |
| Speech impediment | 2 | 2.1 |
| Encephalopathy | 1 | 1.0 |
| Toe walking | 1 | 1.0 |
| Urological | 38 | 39.2 |
| Colic | 17 | 17.5 |
| Renal failure | 13 | 13.4 |
| Crystalluria | 9 | 9.3 |
| Haematuria | 8 | 8.2 |
| Nephrolithiasis | 7 | 7.2 |
| Dysuria | 2 | 2.1 |
| Other urate-related | 29 | 29.9 |
| Gout | 26 | 26.8 |
| Hyperuricemia | 3 | 3.1 |
| Miscellaneous | 11 | 11.3 |
| Affected relative | 7 | 7.2 |
| Failure to thrive | 2 | 2.1 |
| Screening program | 1 | 1.0 |
| Fevers | 1 | 1.0 |
Presenting features in 97 of the 109 unique cases where information concerning presentation was available. The subgroups may sum to more than the total since some cases presented with more than one problem.
Neurological features in previously reported cases
| Extrapyramidal | 18 | 38.3 |
| Choreoathetosis | 9 | 19.1 |
| Dystonia | 9 | 19.1 |
| Athetosis | 4 | 8.5 |
| Pyramidal | 19 | 40.4 |
| Hyperreflexia | 14 | 29.8 |
| Spasticity | 11 | 23.4 |
| Clonus | 2 | 4.3 |
| Other | 28 | 59.6 |
| Dysarthria | 19 | 40.4 |
| Seizures | 7 | 14.9 |
| Ataxia | 2 | 4.3 |
| Tremor | 2 | 4.3 |
Neurological features in 47 of the 109 unique cases were information was presented. The subgroups may sum to more than the total since some cases presented with more than one problem. The table is based on originally reported terminology with no effort to re-interpret accuracy when the term conflicted with actual clinical descriptions.
Figure 1Schematic representation of the spectrum of clinical features in LND and its variants. Patients are divided into subgroups with the most severe being LND, the intermediate form being HPRT-related neurological dysfunction (HND), and the least severely affected being HPRT-related hyperuricaemia (HRH). The frequency or severity of each problem is depicted by the thickness of the tapering bar, with description of the spectrum of the problem across the groups.
Figure 2Histogram showing age at onset of self-injury in previously reported cases of classic LND. Among 349 classic LND cases described in 133 previous reports, the age at onset of self-injury was available for 212 cases. Cases were binned in yearly increments, with a mean age of 3.1 ± 2.5 and a median age of 2 years.
Serum and urine uric acid in classic and variant LND
| Classic LND | 11.7 ± 4.8 | 42.6 ± 17.3 | 3.2 ± 1.1 |
| HPRT-related neurological dysfunction | 13.0 ± 3.8 | 33.6 ± 13.1 | 1.6 ± 0.8 |
| HPRT-related hyperuricaemia | 12.4 ± 5.7 | 23.9 ± 9.8 | 1.0 ± 0.5 |
Uric acid measures for 349 classic and 125 variant cases of LND reported in the prior literature. To avoid skewing the results by over-representation of individual samples, multiple values or ranges of values reported for any one case were averaged to give a single value. When multiple values were reported over several years for one case, only the first value was used, since serum uric acid varies according to age and the values could not be averaged. We excluded values from patients who were receiving drugs known to alter uric acid. Statistical comparisons were conducted via the Kruskal–Wallis test for non-parametric data, which revealed significant group differences for 24 h urinary uric acid (P = 0.003) and uric acid/creatinine ratios (P < 0.001) but not for serum uric acid (P = 0.13).
Figure 3Correlations between dystonia and cognition. Dystonia was rated with the BFM dystonia rating scale, with mild motor deficits scored as mild expressions of dystonia. Scores for patients with LND come from our previous study (Jinnah et al., 2006) while those for variants come from Tables 1 and 2. Cognition was assessed with IQ, which was taken from the results of clinical diagnostic testing or previous publications. Patient subgroups are LND (circles), HPRT-related neurological dysfunction (squares), and HPRT-related hyperuricaemia (triangles). Patients with LND and HPRT-related neurological dysfunction were distinguished by the presence of self-injurious behaviour. The HPRT-related hyperuricaemia group was defined as clinically insignificant motor dysfunction with a BFM score of 5 or less. There was a significant negative correlation between BFM and IQ scores (Spearman rho = −0.64, P < 0.001). This correlation remained after controlling for age (Spearman rho = −0.63, P < 0.001). There was no significant correlation between BFM and age (Spearman rho = 0.20, P = 0.21).
Figure 4Severity of dystonia according to patient subgroup. Dystonia was rated with the BFM dystonia rating scale, with mild motor deficits scored as mild expressions of dystonia. Patient subgroups are LND, HPRT-related neurological dysfunction (HND), and HPRT-related hyperuricaemia (HRH). Patients with LND and HPRT-related neurological dysfunction were distinguished by the presence of self-injurious behaviour. The HPRT-related hyperuricaemia group was defined as clinically insignificant motor dysfunction with a BFM score of 5 or less. Scores for patients with LND come from our previous study (Jinnah et al., 2006) while those for variants come from Tables 1 and 2. Individual scores are overlaid with a box-whisker plot, where the middle horizontal line in each box shows the median. The upper and lower limits of the box define the upper and lower quartiles. Whiskers span the entire data range excepting outliers, defined as values that fell outside the upper or lower quartile plus 1.5 times the inter-quartile distance. The groups were compared statistically using the Kruskal–Wallis H-statistic, which revealed overall significance at P < 0.0001. Post hoc Wilcoxin signed ranked tests revealed significant differences (P < 0.001) between each of the groups.
Figure 5IQ scores according to patient subgroup. The IQ was not methodically assessed with a standardized instrument due to differences in age and language, but instead was taken from the results of clinical diagnostic testing or previous publications. Patient subgroups include LND, HPRT-related neurological dysfunction (HND), and HPRT-related hyperuricaemia (HRH). Patients with LND and HPRT-related neurological dysfunction were distinguished by the presence of self-injurious behaviour. The HPRT-related hyperuricaemia group was defined as clinically insignificant motor dysfunction with a BFM score of 5 or less. Scores for patients with LND come from our previous study (Jinnah et al., 2006) while those for variants come from Tables 1 and 2. Individual scores are overlaid with a box-whisker plot, where the middle horizontal line in each box shows the median. The upper and lower limits of the box define the upper and lower quartiles. Whiskers span the entire data range excepting outliers, defined as values that fell outside the upper or lower quartile plus 1.5 times the inter-quartile distance. The groups were compared statistically using the Kruskal–Wallis H-statistic, which revealed overall significance at P < 0.0001. Post hoc Wilcoxin signed ranked tests revealed significant differences (P < 0.001) between the LND and each of the other two groups. The difference between HPRT-related neurological dysfunction and HPRT-related hyperuricaemia groups was not significant (P = 0.56).
Figure 6Motor features in classic versus variant LND. The percent of patients in the current series of LND variants (LNV; n = 46, black bars) is compared with the percent of patients with classic LND (n = 44, grey bars) from our prior studies (Jinnah et al., 2006). Panel A depicts extrapyramidal features while Panel B depicts pyramidal features.
Mutations of the HPRT gene in classic and variant LND
| Single base substitution | ||||
| Missense | 86 | 76 | 4 | 167 |
| Nonsense | 29 | 1 | 1 | 31 |
| Splice site | 44 | 11 | 0 | 55 |
| Deletions | ||||
| Coding sequences | 80 | 2 | 4 | 86 |
| Splice site | 5 | 0 | 0 | 5 |
| Insertions | ||||
| Coding sequences | 22 | 1 | 0 | 23 |
| Splice site | 1 | 0 | 0 | 1 |
| Miscellaneous | ||||
| Duplications | 3 | 3 | 0 | 6 |
| Substitutions | 4 | 1 | 0 | 5 |
| Regulatory elements | 0 | 3 | 0 | 3 |
| Female cases | 6 | 1 | 0 | 7 |
| Double mutants | 0 | 2 | 0 | 2 |
The genetic mutations in the HPRT gene for both classic cases (LND) and the less seriously affected variants (LNV). The clinical subtype for some patients could not be determined because of insufficient information in some of the reports (NA). A complete list of individual mutations and associated publications can be found at http://www.lesch-nyhan.org.
aSingle base change leading to single amino acid subsitution.
bSingle base change leading to premature termination of protein translation.
cSingle base change leading to intron/exon splicing defect.
dUnidentified promoter or enhancer non-coding sequence change resulting in reduced mRNA.
eAll females have had an identifiable mutation on one allele combined with non-random X-inactivation.